AccuPulse Medical
Atrial Fibrillation Treatment Made Easy

Atrial fibrillation (AF) is one of the most common heart rhythm disorders, with over 33 million people suffering from it in an increasingly aging population. Cardiac catheter ablation, a major interventional therapy, is the fastest growing first line method of treatment for AF. However, despite its efficacy, only a small percentage of AF patients are treated with this therapy due to the capital equipment costs and the lack of skilled certified cardiac EP physicians.

Cardiac catheter ablation uses radio frequency or cryo as the prevalent energy source, the thermal nature of which puts the patient’s safety and long-term clinical results at risk. The procedure also involves multiple pieces of equipment. AccuPulse, a medical equipment manufacturing company, is developing a safer and more integrated system as a response to this dilemma.

“We are introducing a self-contained system that is an inexpensive and safer alternative to traditional AF treatment options. It will be a US designed 3D system that will be manufactured in China and deployed all over Asia,” says Marcus Julian, CTO of AccuPulse Medical.

The AccuPulse team has developed a novel pulsed electric field ablation (PFA) generator and catheters guided by a cuttingedge 3D mapping navigation system with improved catheter localization, signal acquisition, and more intelligent integration.

Ablation procedures carry a potential fatal complication, cardiac wall puncture, especially for patients with the thin posterior left atrial walls. Furthermore, even if physicians restore the normal heart rhythm with RF ablation the treated cardiac tissues may recover due to incomplete transmural lesions, and the patient will develop AF again. While standard energy sources employ time-dependent conductive heating and cooling to ablate all tissue types indiscriminately, PFA selectively ablates cardiac tissues non-thermally by creating nanoscale pores in cell membranes and extracting their cellular content, which is a much safer and more efficient method.
The PFA also limits fluorocarbon exposure to patients, which is typically associated with the procedure, considerably reducing the risks.

Most electrophysiology labs have various discrete systems like ablation catheters, 3D mapping systems, and recording systems. AccuPulse is including an intracardiac echocardiography (ICE) capability, which is currently lacking, to its integrated system and replacing five separate pieces of equipment with one.

AccuPulse’s integrated PFA system solves a major problem electrophysiology labs face with AF treatment today. It is difficult for hospitals to cut costs with multiple equipment in use, but with AccuPulse’s novel technology, the EP labs invest in a single piece of equipment. Its hybrid impedance and magnetic system allow for more accurate localization and visualization of catheters within the heart and help doctors conclude the procedure faster, making it cost-effective for hospitals.

AccuPulse ensures its system is user-friendly, making it easy for physicians to carry out the procedure. It even plans to develop an IoT infrastructure that allows multiple doctors to remotely view clinical procedures.

AccuPulse, despite being a startup, has established a distinct market niche in the electrophysiology industry within a relatively short period. Its team is committed to becoming a global leader in the cardiac electrophysiology industry, taking advantage of the Chinese and American engineering cultures. Its engineering team is based in Utah, with engineers across the US as well as in China.

Its expert team, led and supported by multiple electrophysiological experts and top scientists, is devoted to providing the healthcare sector with the best innovations in AF treatment. The med-tech industry will witness a revolutionary change as AccuPulse enters its next phase.